Cost Effectiveness and Resource Allocation

Table 3 ICER for dexrazoxane administration according to anthracycline dose treatment of sarcoma and haematological malignancies

From: Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective

Malignancy type	France (€)	Germany (€)	UK (£)^a	Italy (€)	Spain (€)
Sarcoma
All AC doses	895	2006	1983	Dominant	Dominant
> 100 mg/m²	891	1991	1986	Dominant	Dominant
> 250 mg/m²	982	2196	2135	Dominant	Dominant
Haematological
All AC doses	559	1418	1590	Dominant	Dominant
> 100 mg/m²	563	1400	1579	Dominant	Dominant
> 250 mg/m²	586	1462	1630	Dominant	Dominant

^a£ sterling amounts converted to Euro at a rate of 1.15€ to one £ for calculations of mean values
AC anthracycline, ICER incremental cost effectiveness ratio

Back to article page

ISSN: 1478-7547

Contact us

General enquiries: journalsubmissions@springernature.com